title: Understanding the host genetics of chronic hepatitis B and C.
abstract: The outcome of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are heterogeneous, ranging from an asymptomatic self-limiting infection to cirrhosis and hepatocellular carcinoma. Several viral environmental and demographic variables have been identified as determinants of disease outcome, but these fail to explain a large proportion of the variability. Evidence from twin studies suggests that the host genetic background is an important contributor to disease outcome. Identification of genes that influence the outcome of infection has been attempted using a wide spectrum of approaches including candidate gene disease association studies, genome-wide scanning in affected sibling pairs and most recently genome-wide association studies. We summarize the main findings from a large number of studies in this review. Many studies have focused on the MHC loci from which several reproducible disease associations have been identified. More recently, genome-wide association studies have identified an important locus within the IL-28 - Il-29 region on chromosome 29, which appears to be a major determinant of the treatment response in patients infected with HCV and also a determinant of spontaneous resolution of infection. Translation of the genetic architecture of chronic viral hepatitis into therapeutic opportunities has been slow to proceed. One clinical trial and one drug development program have been based on genetic discoveries. The use of IL-28B genotyping to predict the response to pegylated interferon and ribavirin may also find its way into clinical practice. Indeed, stratification of clinical trial populations based on IL-28B genotype is already considered mandatory.
authors.affiliation: Hepatology and Gastroenterology Section, Department of Medicine, Imperial College, London, United Kingdom. m.thursz@imperial.ac.uk
authors.forename: Mark
authors.initials: M
authors.lastname: Thursz
authors.forename: Leland
authors.initials: L
authors.lastname: Yee
authors.forename: Salim
authors.initials: S
authors.lastname: Khakoo
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000235:genetics / Q000821:virology; D018450:Disease Progression; D020022:Genetic Predisposition to Disease; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy / Q000235:genetics* / Q000276:immunology; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy / Q000235:genetics* / Q000276:immunology; D015395:Histocompatibility Antigens Class I / Q000235:genetics; D000949:Histocompatibility Antigens Class II / Q000235:genetics; D054884:Host-Pathogen Interactions / Q000235:genetics* / Q000276:immunology; D006801:Humans; D007372:Interferons; D007378:Interleukins / Q000235:genetics; D008103:Liver Cirrhosis / Q000235:genetics / Q000821:virology; D008113:Liver Neoplasms / Q000235:genetics / Q000821:virology; D018579:Patient Selection; D010641:Phenotype; D011110:Polymorphism, Genetic; D011379:Prognosis; D012307:Risk Factors; D000095022:Interferon Lambda
chemical_list: D000998:Antiviral Agents; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D007372:Interferons; D007378:Interleukins; C000624353:interferon-lambda, human; D000095022:Interferon Lambda